Expression of concern regarding paper by Park et al, published on 25 June 2015: “Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015”, Euro Surveill. 2015;20(25):pii=21169. It has been brought to our attention that some of the authors may not have been informed about the content of the above paper. There is a lack of clarity regarding rights to use the data. The editorial team are investigating what action needs to be taken.

Read our articles on the ongoing Ebola outbreak in West Africa

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Weekly Release  2003: Volume 7/ Issue 23 Article 2
Back to Table of Contents

Eurosurveillance, Volume 7, Issue 23, 05 June 2003

Citation style for this article: New surveillance system for antibiotic resistance in Switzerland. Euro Surveill. 2003;7(23):pii=2238. Available online:

New surveillance system for antibiotic resistance in Switzerland

Translated and adapted from reference 1 by Editorial team (, Eurosurveillance editorial office.

A Switzerland wide surveillance system, to register and analyse all circulating antibiotic resistant microorganisms will be set up in the next two years (1). The methodology of the monitoring will provide the basis for research, formulating prevention policy, and control.

A research team at the institute of infectious diseases at the university of Bern together with a steering group is developing a monitoring system, which includes 60% of hospital patients and 30% of practicing general practitioners in Switzerland. Previous studies have been limited to specific pathogens, patient groups, or regions.

Compared internationally, the levels of antibiotic resistance in Switzerland are relatively low, although an increase has been observed in recent years. Because resistance can spread quickly in a population, it is important to intervene while resistance is relatively low.

A feasibility study was conducted as part of a one-year pilot project. From more than 80 Swiss microbiology laboratories, the team selected 20 covering the highest number of patients in all areas of the country. The laboratories agreed to send the anonymised results of the resistance tests electronically to a central database, where they will be analysed. During the pilot project the research team, which is led by Dr Kathrin Muehlemann, also checked the comparability of the tests to be conducted at the participating laboratories and found a software developer for the data management system.

The epidemiology of the different bacteria strains sheds light on trends in the evolution of resistance, which could help in the development of new antibiotics. The research team will also observe antibiotic use and compare this with data on resistance development. Information on this relationship will also be used by other countries such as Denmark, and by individual hospitals.

The database will be completed by August 2005. During the final year of the project it is planned to link the monitoring data to European databases on antibiotic resistance (such as the European Antimicrobial Resistance Surveillance System (EARSS, and antibiotic consumption (such as the European Surveillance of Antimicrobial Consumption (ESAC). There are also plans to extend the surveillance to fungal infections.

  1. Schweizerischer Nationalfonds zur Foerderung der wissenschaftlichen Forschung. Die Schweiz erhält ein nationales Überwachungssystem für Antibiotikaresistenzen. Press release, 13 May 2003. ( [German], ( [French].

back to top

Back to Table of Contents

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal.
The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement.

Eurosurveillance [ISSN] - ©2007-2013. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.